CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 7 enrolled
Drug / intervention
Purified Pancreatic Islets +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00888628
NCT00888628Phase 2Completed

Islet Transplantation in Type 1 Diabetic Kidney Allograft Recipients

Massachusetts General Hospital·interventional·Posted Apr 27, 2009·Updated Nov 29, 2017

In Brief

A Phase 2 clinical trial evaluating Purified Pancreatic Islets and Etanercept for Diabetes Mellitus, Type I. Completed, enrolled 7 participants across 1 site.

Detailed Summary

The purpose of the study is to learn if islet transplantation is an effective treatment for Type 1 diabetes in people who have had a kidney transplant. The primary objectives of the study are: \- To set up islet transplantation in patients who have had a kidney transplant and who are using an immunosuppressive regimen that works The Secondary objective of the study is: * To find out if successful islet transplantation leads to improved metabolic control and reduced renal complication from diabetes

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 27, 2009
Enrollment StartMay 1, 2009
Primary CompletionAug 1, 2014
Study CompletionAug 1, 2016
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 17.2 years ago

Interventions

Purified Pancreatic Isletsbiological

Islet after kidney transplant in patients with type I diabetes.

Etanerceptdrug

Given as induction for islet cell transplant